Mae Sheikh Ali, MD
Endocrinology, Diabetes & Metabolism · Jacksonville, FLNPI 1164405122
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $597,731 of the $750,781 with a category attached, or 79.6%. 46 manufacturers reported payments, led by Novo Nordisk at 40.1% of the total. Reporting peaked in 2019 at $208,367 and has fallen 82.7% since, to $36,101 in 2025. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,427 payments — averaging $526.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$301K
- Lilly USA, LLC$144K
- Amgen$103K
- Abbott$91K
- Mannkind Corporation$26K
- AstraZeneca$19K
- plus $66K from 40 others
Across 1,164 payments — averaging $1880.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.8M
- Novo Nordisk AS$327K
- Pfizer$52K
- Novartis$18K
- Boehringer Ingelheim$10K
- Boehringer Ingelheim International GmbH$5K
What the payments were for
- Consulting fees$25,5133%
- Speaking & faculty fees$597,73180%
- Travel & lodging$99,43813%
- Food & beverage$26,2623%
- Education$2720%
- Gifts$1,5660%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$180,842
- MOUNJARO$109,464
- RYBELSUS$86,132
- Prolia$59,498
- FREESTYLE LIBRE 3$44,575
- EVENITY$39,590
- FreeStyle Libre Pro$27,600
- AFREZZA$25,012
- FARXIGA$18,639
- STEGLATRO$15,787
- Tirosint$11,928
- Xultophy 100/3.6$11,029
- HUMULIN$10,729
- INVOKANA$10,504
- FreeStyle Libre$10,285
- Tresiba$10,131
- FreeStyle Libre 2$5,566
- 25-OH Vitamin D ST AIA-Pack$5,481
- Tymlos$3,780
- Synthroid$1,853
How this compares
$750,781 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 102 | $138,207 |
| MounjaroTirzepatide | 80 | $100,398 |
| JardianceEmpagliflozin | 86 | $98,767 |
| Tresiba Flextouch U-200Insulin Degludec | 45 | $38,126 |
| FarxigaDapagliflozin Propanediol | 19 | $17,263 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 21 | $10,634 |
| NovologInsulin Aspart | 25 | $9,815 |
| VascepaIcosapent Ethyl | 11 | $7,510 |
| Novolog FlexpenInsulin Aspart | 28 | $7,397 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $7,175 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $4,682 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $4,612 |
| HumalogInsulin Lispro | 15 | $3,738 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 17 | $2,991 |
| SynthroidLevothyroxine Sodium | 24 | $2,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $301,246 | $148,022127 claims |
| Lilly USA, LLCMounjaro, Humalog | $144,116 | $104,13695 claims |
| Boehringer IngelheimJardiance | $392 | $98,76786 claims |
| AstraZenecaFarxiga | $19,194 | $17,26319 claims |
| AbbVieSynthroid | $1,957 | $2,36024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Jacksonville
- David SuttonJacksonville$783K
- Wasim DeebJacksonville$286K
- Khurram WadudJacksonville$77K
- Senan SultanJacksonville$55K
- Firas WardaJacksonville$38K
- Maria Hurtado AndradeJacksonville$36K
- Jay SkylerMiami$2.2M
- Arelis MaderaPort Charlotte$1.7M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.